NAV

Savolitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Savolitinib
DrugBank Accession Number
DB12048
Background

Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 345.37
Monoisotopic: 345.145041519
Chemical Formula
C17H15N9
Synonyms
  • Savolitinib
  • Volitinib
External IDs
  • AZD6094
  • HMPL-504

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Savolitinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Savolitinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Savolitinib.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Savolitinib.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Savolitinib.
MethimazoleThe therapeutic efficacy of Methimazole can be decreased when used in combination with Savolitinib.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Savolitinib.
Potassium IodideThe therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Savolitinib.
Potassium perchlorateThe therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Savolitinib.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as imidazopyridines. These are organic polycyclic compounds containing an imidazole ring fused to a pyridine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyridines
Sub Class
Not Available
Direct Parent
Imidazopyridines
Alternative Parents
Imidazo[1,2-a]pyridines / Pyridines and derivatives / Pyrazines / N-substituted imidazoles / Triazoles / Pyrazoles / Heteroaromatic compounds / Azacyclic compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
1,2,3-triazole / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Imidazo[1,2-a]pyridine / Imidazole / Imidazopyridine / N-substituted imidazole
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2A2DA6857R
CAS number
1313725-88-0
InChI Key
XYDNMOZJKOGZLS-NSHDSACASA-N
InChI
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
IUPAC Name
4-{1-[(1S)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyrazole
SMILES
C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1

References

General References
Not Available
PubChem Compound
68289010
PubChem Substance
347828359
ChemSpider
34501055
BindingDB
50023342
ChEMBL
CHEMBL3334567
ZINC
ZINC000149738712
PDBe Ligand
V0L
Wikipedia
Savolitinib
PDB Entries
5lbw / 6sde

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentCarcinoma / Enzyme Inhibitors / Kidney Diseases / Neoplasms by Site / Protein Kinase Inhibitors / Renal Cell Carcinoma (RCC) / Renal Neoplasms / Urologic Neoplasms1
3RecruitingTreatmentCarcinoma / Non Small Cell Lung1
3RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
3RecruitingTreatmentNon-Small Cell Lung Cancer (NSCLC)2
3RecruitingTreatmentPapillary Renal Cell Carcinoma1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma1
2Active Not RecruitingTreatmentLocally Advanced Papillary Renal Cell Carcinoma / Metastatic Papillary Renal Cell Carcinoma / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V7 / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Unresectable Renal Cell Carcinoma1
2Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2Active Not RecruitingTreatmentSarcomatoid carcinoma of the lung1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.337 mg/mLALOGPS
logP1.88ALOGPS
logP1.07Chemaxon
logS-3ALOGPS
pKa (Strongest Basic)6.67Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area91.61 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity119.06 m3·mol-1Chemaxon
Polarizability35.72 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:15 / Updated at February 21, 2021 18:53